Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients

Balogh,Gabriela A.; Mailo,Daniel; Nardi,Hector; Corte,Maria M.; Vincent,Esteban; Barutta,Elena; Lizarraga,Guillermo; Lizarraga,Pablo; Montero,Hector; Gentili,Roberto

doi:10.3892/etm_00000056

Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients

Authors:
- Gabriela A. Balogh
- Daniel Mailo
- Hector Nardi
- Maria M. Corte
- Esteban Vincent
- Elena Barutta
- Guillermo Lizarraga
- Pablo Lizarraga
- Hector Montero
- Roberto Gentili
View Affiliations

Affiliations: CERZOS-CONICET, Centro Científico Tecnológico Bahía Blanca, Bahia Blanca-8000, Argentina
Published online on: March 1, 2010 https://doi.org/10.3892/etm_00000056
Pages: 357-361

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ≤30 years of age. Anti-p53-antibodies were detected in patients ≤40 and ≥61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery.

View Figures

View References

1.	Ries L, Eisner M, Kosary C, et al: SEER. Cancer Statistics Review. National Cancer Institute; Bethesda, MD: pp. 1973–1999. 2002
2.	Greenie RT, Murray T, Boldin S and Wingo P: Cancer statistics 2000. Cancer J Clin. 50:7–23. 2000. View Article : Google Scholar
3.	Stewart BW and Kleihues P: World Cancer Report. IARC Press; France: 2003
4.	Oliveira AM, Ross JS and Fletcher JA: Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol. 124:S16–S28. 2005.PubMed/NCBI
5.	Bourdon JC, Laurenzi VD, Melino G and Lane D: p53: 25 years of research and more questions to answer. Cell Death Differ. 10:397–399. 2003.PubMed/NCBI
6.	Bourdon JC: p53 and its isoforms in cancer. Br J Cancer. 97:277–282. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Soussi T: The p53 pathway and human cancer. Br J Surg. 92:1331–1332. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B and Slamon DJ: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 13:1971–1981. 1997.PubMed/NCBI
9.	Dowell SP, Wilson PO, Derias NW, Lane DP and Hall PA: Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 54:2914–2918. 1994.PubMed/NCBI
10.	Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 30:403–408. 1982. View Article : Google Scholar : PubMed/NCBI
11.	Soussi T: Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60:1777–1788. 2000.PubMed/NCBI
12.	Vogl FD, Frey M, Kreienberg R and Runnebaum IB: Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer. 83:1338–1343. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Balogh GA, Corte MM, Nardi H, et al: Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int J Oncol. 8:995–1002. 2006.PubMed/NCBI
14.	Lagios MD: Pathologic practice standards for breast carcinoma: tumor size, reliable data, or miscues? J Am Coll Surg. 196:91–92. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Silverstein MJ and Lagios MD: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17. Cancer. 88:242–244. 2000.
16.	Soussi T: p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60:1777–1788. 2000.PubMed/NCBI
17.	Crawford LV, Pimand DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 30:403–408. 1982. View Article : Google Scholar : PubMed/NCBI
18.	Choi JH, Oh JY, Ryu SK, et al: Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer. 79:1879–1883. 1997. View Article : Google Scholar : PubMed/NCBI
19.	Oh MJ, Choi JH, Kim IH, et al: Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res. 6:4760–4763. 2000.PubMed/NCBI
20.	Sobti RC, Parashar K, Kaurand R and Capalash N: Detection of human papillomavirus DNA, serum p53 and p53 antibodies in patients with cervical cancer. J Environ Pathol Toxicol Oncol. 21:79–85. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Oh MJ, Choi JH, Lee YH, Lee JK, Hur JY, Park YK, Lee KW, Chough SY and Saw HS: Mutant p53 protein in the serum of patients with cervical carcinoma: correlation with the level of serum epidermal growth factor receptor and prognostic significance. Cancer Lett. 203:107–112. 2004. View Article : Google Scholar
22.	Micelli G, Donadeo A and Quaranta M: The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. Cell Biophys. 21:25–31. 1992. View Article : Google Scholar : PubMed/NCBI
23.	Al-Moundhri M, Nirmala V, Al-Mawaly K, Ganguly S, Burney I, Rizvi A and Grant C: Significance of p53, Bcl-2 and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res. 9:226–231. 2003. View Article : Google Scholar : PubMed/NCBI
24.	Labrecque S, Naor N, Thomson D and Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res. 53:3468–3471. 1993.PubMed/NCBI
25.	Trivers GE, Cawley HL, De Benedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC and Harris CC: Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst. 87:1400–1407. 1995. View Article : Google Scholar : PubMed/NCBI
26.	Gormally E, Vineis P, Matullo G, et al: TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 66:6871–6876. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Mocci F and Nettuno M: Plasma mutant-p53 protein and anti-p53 antibody as a marker: an experience in vinyl chloride workers in Italy. J Occup Environ Med. 48:158–164. 2006. View Article : Google Scholar : PubMed/NCBI